Autologous Serum & Other Blood-Derived Eye Drops

Autologous means that the material comes from the same person who receives it. Blood is collected from the patient and allowed to clot. It is then centrifuged so that the cellular components and clot are separated from the liquid portion. That liquid portion is serum. The serum can then be processed, diluted depending on the protocol, divided into sterile containers and stored for use as eye drops. So:

your blood→processing→serum→eye drops

There are no red blood cells in properly prepared serum eye drops.

Because serum contains substances that ordinary lubricating drops generally do not. These can include:

• •growth factors
• •vitamins
• •fibronectin
• •proteins
• •antioxidants
• •and other biologically active molecules

Several of these are involved in maintaining and repairing epithelial tissue. That gives serum drops a fundamentally different rationale from an ordinary lubricant. Reviews of autologous serum describe components such as epidermal growth factor, fibronectin, vitamin A and other trophic factors that are absent from conventional artificial tears.

No. This is an important distinction. Serum and tears have some overlapping biological components, but their composition is not identical. Some substances occur at different concentrations. And serum is derived from blood, not from the lacrimal functional unit.

So I would avoid the common description “serum is exactly like your natural tears.” It isn’t. A better description is that serum provides lubrication plus biological components that ordinary artificial tears cannot reproduce.

Imagine two different problems. In the first, the ocular surface is relatively healthy but needs additional lubrication. An ordinary artificial tear may be perfectly reasonable.

In the second, the corneal epithelium is chronically stressed or damaged. Now the treatment target is not simply to make the eye wetter. We may also want to create an environment that supports:

• •epithelial maintenance
• •healing
• •and ocular-surface homeostasis

That is where biologic tear substitutes become particularly interesting.

No, and I think this is one of the most useful distinctions to understand. Artificial tears primarily attempt to:

• •lubricate
• •increase tear volume
• •reduce friction
• •or supplement particular physical components of the tear film

Autologous serum can do some of that too. But its proposed advantage is the presence of biologically active components. So this is not simply a ladder from ordinary drops to stronger drops to serum drops. They are different categories of treatment.

Artificial Tears & Lubricating Eye Drops

They are commonly considered in more significant ocular-surface disease, including:

• •moderate-to-severe dry eye
• •severe aqueous-deficient dry eye
• •Sjögren-associated dry eye
• •persistent epithelial defects
• •neurotrophic keratopathy

They are generally not the first thing someone with occasional mild dry-eye symptoms needs. TFOS DEWS III includes autologous serum and platelet-rich plasma among biologic tear substitutes used in dry-eye management.

Treating Aqueous-Deficient Dry Eye

Sjögren's Disease and Dry Eye

Serum drops are often diluted before use. For example, 20% serum means that serum constitutes 20% of the final preparation. Other protocols use:

• •50%
• •100%
• •or other concentrations

And here we encounter an important problem in the literature: there is no single universally standardized autologous-serum protocol. Studies and clinics differ in:

• •blood collection
• •clotting time
• •centrifugation
• •dilution
• •storage
• •concentration
• •and sometimes frequency of application

Published clinical guidance specifically notes substantial variation in preparation methods and final serum concentrations.

One historical rationale is that some serum components occur at concentrations different from those found in natural tears. Dilution may bring certain components closer to physiological tear concentrations. But there is no simple rule that 20% is correct and 100% is wrong. Different concentrations have been studied.

A 2025 review of randomized trials found symptom improvement with 20% serum and noted particularly consistent improvements in clinical signs in studies using 50%, but the authors emphasized that the evidence remains limited by small studies and variable protocols.

So “higher concentration means better” has not been established as a universal rule.

This is where the evidence is interesting, and somewhat messy. Older systematic reviews were cautious.

A Cochrane review found only five eligible randomized trials with 92 participants. The certainty of evidence was low or very low, and results were inconsistent. There was some short-term evidence of symptom improvement, but objective outcomes were not consistently better than artificial tears.

An updated systematic review published in 2023 included six randomized trials with 116 participants and reached a similarly cautious conclusion: the effectiveness of autologous serum remained uncertain because the studies were small and reporting was inconsistent.

But newer analyses include more trials.

A 2024 systematic review and meta-analysis included 12 randomized controlled trials. Compared with artificial tears, autologous serum was associated with improvements in:

• •Schirmer test
• •tear break-up time
• •corneal fluorescein staining
• •and OSDI symptom scores

That is encouraging. But it does not make the older uncertainty disappear. The literature still contains relatively small trials, different patient populations, different serum concentrations and different preparation protocols.

So the most accurate conclusion is probably that autologous serum appears beneficial for some patients with dry eye, particularly more significant ocular-surface disease, but the evidence base is still less standardized than we would ideally like.

This is a good example of how medical evidence evolves. The 2023 review searched trials only through September 2022 and included six RCTs. The 2024 meta-analysis searched through April 2024 and included twelve. So they are not necessarily contradicting one another. They are looking at different amounts of evidence.

It is also a useful reminder that “a systematic review found no clear benefit” does not always mean “the treatment doesn’t work.” Sometimes it means “the available trials were too small or inconsistent to give us a confident answer.”

Not necessarily. This is another important distinction. Serum drops are primarily biologic tear substitutes. They are placed onto the ocular surface. They do not directly stimulate the lacrimal gland in the way a secretagogue or neural stimulation treatment attempts to do.

So if your Schirmer test improves during treatment, that is interesting. But the fundamental treatment concept is not to make the lacrimal gland produce more. It is to provide the ocular surface with a biologically richer substitute.

Stimulating Natural Tear Production

Serum drops are used clinically in conditions involving epithelial damage, including persistent epithelial defects. They provide factors that may support epithelial maintenance and healing, and clinical guidance describes both lubricating and epithelial-healing roles.

But I would still avoid saying “serum heals every damaged cornea.” Whether healing occurs depends on why the epithelium is damaged. If there is:

• •severe exposure
• •mechanical trauma
• •infection
• •limbal stem-cell deficiency
• •or profound neurotrophic disease

serum may be only one part of treatment. Again, the target matters.

Eyelid Closure, Lagophthalmos & Exposure

This is particularly interesting. In neurotrophic keratopathy, corneal innervation is impaired. The problem is not simply that the eye feels dry. Corneal nerves participate in epithelial maintenance and healing. When that system is disrupted, the corneal surface may become damaged, sometimes while the patient experiences surprisingly little pain.

Biological tear substitutes can provide supportive trophic factors to the ocular surface. That does not mean serum regrows corneal nerves. It means it may help support an ocular surface whose normal biological support system is impaired.

Corneal Nerves

This is a different question. Someone can have severe ocular pain without major epithelial damage. Serum is sometimes used in patients with suspected neuropathic corneal pain, and there is research interest in its possible relationship to corneal nerve morphology. But evidence in this area is much less robust than evidence for serum as an ocular-surface therapy.

So we should distinguish serum for a damaged or dysfunctional ocular surface from serum as a treatment for neuropathic pain itself. Those are not yet equally established claims.

Neuropathic Corneal Pain

Autologous serum is not the only blood-derived eye-drop treatment. Another increasingly discussed option is platelet-rich plasma, or PRP. PRP is prepared differently from serum and is designed to retain a high concentration of platelets. Platelets contain numerous growth factors and biologically active molecules. This creates the rationale that PRP may provide a particularly rich regenerative environment for damaged ocular-surface tissue.

TFOS DEWS III includes both autologous serum and platelet-rich plasma among biologic tear substitutes.

We cannot confidently say that. PRP is sometimes marketed as:

• •“more regenerative,”
• •“stronger,”
• •“next-generation serum.”

Biologically, the higher concentration of platelet-derived factors is interesting. But more growth factors does not automatically mean a better clinical treatment. Preparation protocols vary substantially, and direct high-quality comparative evidence remains limited.

So I would not create a hierarchy of artificial tears, then serum, then PRP. That is not what the evidence establishes. They are different preparations with different compositions and potentially different roles.

You may also encounter terms such as:

• •PRGF, plasma rich in growth factors
• •platelet lysate
• •or other blood-derived formulations

This field contains multiple preparation methods. And unfortunately, terminology is not always consistent. Two clinics can say they offer “plasma eye drops” while using quite different processing protocols. That makes it particularly important to ask: what exactly is being prepared?

Sometimes a patient cannot provide suitable blood for autologous serum. For example, there may be:

• •difficulty obtaining sufficient blood
• •severe anemia
• •or other medical limitations

In some settings, allogeneic serum, meaning serum from a screened donor, can be used. This introduces additional considerations involving donor screening, processing and safety. It is therefore not simply interchangeable with autologous serum.

Umbilical cord serum has also been investigated as a biological ocular-surface treatment. It contains high concentrations of several growth factors. But again, it involves a completely different source and additional requirements for donor screening and processing.

For a patient reading about “serum tears,” it is worth realizing that autologous serum, donor serum, cord serum, PRP and PRGF are not the same product.

Because these are biological products. They do not contain conventional preservative systems designed for long-term room-temperature storage. Preparation and storage therefore matter. Protocols commonly involve freezing unused portions and keeping the bottle currently in use refrigerated, although exact instructions vary according to the preparation protocol.

This is not just about maintaining convenience. It relates to stability and microbial safety. Published practice guidance specifically addresses preparation, transport, storage and use because these issues are central to safe serum therapy.

Yes. Any preservative-free biological preparation has potential contamination concerns. That is why serum eye drops should be produced using appropriate sterile procedures and stored according to the preparation protocol.

This is not something I would recommend making casually at home from blood. The fact that the material came from your own body does not make bacterial contamination harmless.

Typically, no. And that is one reason storage and handling become so important. Ordinary commercial eye drops can be manufactured and packaged under standardized industrial conditions. A personalized blood-derived product requires a different safety system.

So being preservative-free is an advantage for the ocular surface, but it also creates handling responsibilities.

They are generally considered well tolerated when appropriately prepared and handled. The American Academy of Ophthalmology reviewed serum-based eye drops for severe dry eye and persistent epithelial defects and found improvements in symptoms or signs in multiple studies, but also emphasized that the available evidence consisted mainly of Level II and III studies rather than the strongest level of evidence. The randomized-trial evidence has expanded since then, but standardization remains an issue.

Potential concerns include:

• •contamination
• •infection
• •handling errors
• •and difficulties maintaining the required cold chain

There is no single universal schedule. Protocols vary substantially. Some patients use them several times per day. In more severe ocular-surface disease, they may be used very frequently. But frequency should follow the specific preparation protocol and clinical indication.

This is another area where “My friend uses serum eight times a day” does not tell you how often another patient should use it.

Again, there is no universal answer. Some patients use serum temporarily while the ocular surface heals. Others with chronic severe disease use it for much longer periods. This depends on whether the underlying problem is temporary or persistent.

If someone has permanent severe lacrimal insufficiency, for example, biological tear replacement may remain useful long term. If serum is being used to support recovery from a temporary epithelial problem, treatment may eventually be reduced or stopped.

Not directly. They do not:

• •open blocked meibomian glands
• •normalize thick meibum
• •or restore the lipid layer

But someone with MGD can also have significant ocular-surface damage. In that case, serum may address the surface consequences while another treatment addresses the glands. This distinction is extremely important: a treatment can be valuable without treating the original driver.

Treating Meibomian Gland Dysfunction

Absolutely. And that does not mean the treatment has failed. Imagine someone has severe aqueous deficiency. Serum drops improve epithelial health and comfort dramatically. The lacrimal gland still produces too little. But the patient’s ocular surface is healthier. That is a real therapeutic success.

We just need to describe it accurately: supporting and protecting the ocular surface is not the same as repairing the lacrimal gland.

The answer depends on why it was prescribed. Useful outcomes may include:

• •less corneal or conjunctival staining
• •healing of epithelial defects
• •improved tear-film stability
• •less pain or discomfort
• •better vision
• •reduced dependence on ordinary lubricants
• •and better everyday function

If the treatment target was epithelial healing, then looking only at Schirmer score would make very little sense. Again: measure the target you are actually treating.

How to Choose a Dry Eye Treatment